OREANDA-NEWS. SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN, OTCPK: SMDCY) (“SHL”), a leading provider and developer of advanced personal telemedicine solutions, announced today that the Board of Directors has unanimously resolved to appoint Mr. Uzi Blumensohn to serve as a member of the Board until the next Annual General Meeting.

From 2007 to 2008, Mr. Uzi Blumensohn was a VP Cardiology of McKesson Corporation (NYSE:MCK), ranked 11th on the FORTUNE 500 list, a healthcare services and information technology company. From 1995 to 2006, Mr. Blumensohn was the Chairman of the Board and CEO of Medcon Ltd., a cardiac image and information management solutions company, traded on the Tel Aviv Stock exchange and sold to McKesson Corporation. Mr. Blumensohn is currently the Chairman of the Board of Endymed Medical Ltd. (TLV:ENDY) a medical technology company that designs, develops, and commercializes energy based aesthetic treatment systems for the professional markets. He holds a B.Sc. in Mathematics & Computer Science, an MBA and an MA in Conflict Resultions – all from the Tel-Aviv University. Nationality: Israeli.

About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. The Company operates in Israel, Germany, India and the United States in one business segment, Telemedicine services. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and has an ADR program listed over-the counter; Symbol: SMDCY.